RJK002 / Rejukon Biopharm - LARVOL DELTA

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: RJK Biopharma Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: May 2031 ➔ Nov 2030 | Trial primary completion date: Nov 2025 ➔ Nov 2026

Enrollment closed • Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: RJK Biopharma Ltd | Trial primary completion date: Jul 2026 ➔ Jun 2025

Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: RJK Biopharma Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders • NEFL

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: RJK Biopharma Ltd | Not yet recruiting ➔ Active, not recruiting | Initiation date: Sep 2024 ➔ Nov 2023

Enrollment closed • Trial initiation date • Amyotrophic Lateral Sclerosis • CNS Disorders

Phase I Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Rejukon Biopharm Inc.

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • NEFL

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Rejukon Biopharm Inc.

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

Orphan Designation: Treatment of Amyotrophic Lateral Sclerosis (FDA) - Date Designated: 10/16/2023

Orphan drug • Amyotrophic Lateral Sclerosis